MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer
- 1 November 2005
- journal article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 22 (7) , 565-573
- https://doi.org/10.1007/s10585-005-5376-z
Abstract
Molecular changes are vital for the development of prognostic markers and therapeutic modalities of prostate cancer (CaP). There is growing interest in mucins as treatment targets in human malignancies, including CaP. The role of their expression in the progression of CaP is however unclear. We examined the expressions MUC1, MUC2, MUC4, MUC5AC and MUC6 in CaP tissues using tissue microarrays (TMAs) to look for tumor-associated antigens (TAAs) for targeted therapy. In this study, 120 paraffin-embedded specimens were selected from patients who underwent radical retro-pubic prostatectomy (RRP) or trans-urethral-resection of the prostate (TURP) for primary, untreated CaP and 10 matched lymph node metastases. A series of MUC monoclonal antibodies (mAbs) was used on TMAs by standard immunohistochemistry. Our results indicate that the over-expression of MUC1 was detected in 58% of primary CaP tissues and 90% of lymph node metastases but not in normal prostate or benign tissues, while the expression of MUC2, MUC4, MUC5AC and MUC6 was found to be negative in both normal and cancer tissues. Of the MUC1 positive tumors 86% were Gleason grade 7 or higher. Over-expression of MUC1 was found in late stage CaP while MUC2, 4, 5AC and 6 were negative in CaP. MUC1 is a TAA that is highly related to tumor progression in CaP patients. This antigen is ideal for targeted therapy to control micrometastases and hormone refractory disease but additional studies are necessary to assess its usefulness in patient biopsies and CaP bone metastases before clinical trial.Keywords
This publication has 54 references indexed in Scilit:
- Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosisInternational Journal of Urology, 2005
- MUC1 expression in human prostate cancer cell lines and primary tumorsProstate Cancer and Prostatic Diseases, 2004
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- A STAT-responsive Element in the Promoter of the Episialin/MUC1 Gene Is Involved in Its Overexpression in Carcinoma CellsJournal of Biological Chemistry, 2001
- New Aspects of Siglec Binding Specificities, Including the Significance of Fucosylation and of the Sialyl-Tn EpitopeJournal of Biological Chemistry, 2000
- MUC1 Mucin Expression in Transitional Cell Carcinoma of the Bladder: A Target Antigen for Diagnosis and Therapy with Monoclonal Antibody C595Journal of Urologic Pathology, 2000
- MUC1 and cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1999
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.Molecular Biology of the Cell, 1996
- Epithelial Mucin GenesAnnual Review of Physiology, 1995